Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer
Molecular Imaging and Radionuclide Therapy · 2017
DOI: 10.4274/2017.26.suppl.09 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Imaging and Radionuclide Therapy, 2017. Verfasst von Steven M Larson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, USA, Phone: 646888359, E-mail: larsons@mskcc.org. Die Arbeit wurde bisher 13-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Memorial Sloan Kettering Cancer Center, New York, USA, Phone: 646888359, E-mail: larsons@mskcc.org.
Förderung
- NCI NIH HHS
Zitieren
APA
Larson, S. M., Osborne, J. R., Grewal, R. K., & Tuttle, R. M. (2017). Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer. Molecular Imaging and Radionuclide Therapy. https://doi.org/10.4274/2017.26.suppl.09
Vancouver
Larson SM, Osborne JR, Grewal RK, Tuttle RM. Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer. Molecular Imaging and Radionuclide Therapy. 2017. doi:10.4274/2017.26.suppl.09
BibTeX
@article{Larson2017,
author = {Larson, Steven M and Osborne, Joseph R and Grewal, Ravinder K and Tuttle, R Michael},
title = {Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer},
journal = {Molecular Imaging and Radionuclide Therapy},
year = {2017},
doi = {10.4274/2017.26.suppl.09}
}
EUVIMED